Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 4.07B | 3.83B | 3.66B | 3.09B | 2.36B |
Gross Profit | 3.62B | 3.40B | 3.12B | 2.65B | 2.21B |
EBITDA | 1.37B | 1.23B | 553.78M | 1.03B | 649.65M |
Net Income | 560.12M | 414.83M | -214.14M | -328.95M | 238.62M |
Balance Sheet | |||||
Total Assets | 12.01B | 11.39B | 10.84B | 12.30B | 6.54B |
Cash, Cash Equivalents and Short-Term Investments | 2.99B | 1.63B | 881.48M | 591.45M | 2.13B |
Total Debt | 6.16B | 5.79B | 5.80B | 6.14B | 2.23B |
Total Liabilities | 7.92B | 7.66B | 7.75B | 8.33B | 2.88B |
Stockholders Equity | 4.09B | 3.74B | 3.09B | 3.97B | 3.66B |
Cash Flow | |||||
Free Cash Flow | 1.35B | 1.07B | 773.78M | 732.98M | 520.39M |
Operating Cash Flow | 1.40B | 1.09B | 1.27B | 778.51M | 899.65M |
Investing Cash Flow | -508.19M | -163.06M | -446.23M | -5.21B | -1.01B |
Financing Cash Flow | 20.52M | -305.25M | -529.49M | 3.97B | 528.07M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $6.96B | 14.84 | 147.06% | ― | 25.65% | 57.10% | |
75 Outperform | $6.83B | 15.19 | 12.25% | ― | 5.76% | 49.58% | |
60 Neutral | $8.83B | ― | 35.68% | ― | -41.71% | -9.37% | |
60 Neutral | $7.65B | ― | -20.00% | ― | 112.46% | 54.33% | |
56 Neutral | $7.42B | ― | -50.16% | ― | ― | 21.83% | |
54 Neutral | $7.78B | 1.93 | -8.56% | ― | -38.94% | -104.46% | |
52 Neutral | $7.37B | -0.04 | -63.81% | 2.59% | 16.40% | <0.01% |
On July 8, 2025, Jazz Pharmaceuticals announced the appointment of Renee Gala as the new President and Chief Executive Officer, effective August 11, 2025. This leadership change follows a robust succession process and marks a significant milestone in the company’s long-term succession planning. Bruce Cozadd, the current CEO, will retire on September 12, 2025, but will continue as Chairperson of the Board. Gala, who has been with Jazz since 2020, has played a pivotal role in the company’s transformation and growth, and her appointment is expected to drive further value creation and sustainable growth for Jazz Pharmaceuticals.
The most recent analyst rating on (JAZZ) stock is a Buy with a $200.00 price target. To see the full list of analyst forecasts on Jazz Pharmaceuticals stock, see the JAZZ Stock Forecast page.